Senior Correspondent, London
Ben's Feed
Jun 15, 2014
Jun 13, 2014

Drug-linked payouts: complex fix for Pfizer’s next Astra bid?

LONDON (Reuters) – The world’s biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal a deal with AstraZeneca remains intense.

Even as talks fell apart last month, some in Pfizer’s camp remained optimistic the transaction could be revived – and certain AstraZeneca advisers have not ruled out renewed talks. Under British takeover law, the UK firm can approach Pfizer at the end of August to discuss a sweetened bid, or Pfizer can try again in November.

Jun 13, 2014
Jun 13, 2014
Jun 12, 2014
Jun 12, 2014

AstraZeneca builds pipeline with $232 mln Synairgen asthma deal

LONDON, June 12 (Reuters) – AstraZeneca has struck a
deal worth up to $232 million in milestone payments to acquire
rights to a drug from Synairgen for treating
respiratory tract viral infections in patients with severe

Britain’s second-biggest drugmaker – subject of a $118
billion bid by Pfizer that failed last month – said on
Thursday it would pay UK-based Synairgen a $7.25 million upfront
fee and potential development, regulatory and commercial
milestones of up to $225 million for rights to the drug,
codenamed SNG001.

Jun 9, 2014
Jun 9, 2014
Jun 1, 2014

Europe’s new one-stop patent winning over companies

LONDON, June 2 (Reuters) – Europe’s new one-stop patent
system is winning over companies despite initial criticism from
lawyers and some multinationals of the scheme, which is expected
to come into effect in 2016, according to a survey on Monday.

The Europe-wide unitary patent system offers a cheaper,
simpler solution for businesses seeking to protect their
inventions, rather than having to register and enforce patents
separately in individual European Union countries.

May 29, 2014

GSK invites private equity bids for older drugs: sources

LONDON (Reuters) – GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter.

The move is part of a reshaping of the drugmaker’s business, which also involves a major asset swap deal struck last month with Novartis.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben